{
  "id": 6382,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Informative and concerned"
    },
    "dialogue_turns": [
      {
        "speaker": "HostA",
        "text": "So this is a real cautionary tale from the HIV vaccine effort over a decade ago.",
        "tts_text": "So this is a real cautionary tale from the H I V vaccine effort over a decade ago.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The researchers warn of a cautionary tale from efforts to create an HIV vaccine over a decade ago, where a promising vaccine candidate actually increased the risk of some men catching the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Yeah, where a promising candidate actually increased the risk of some men catching the virus. That's uh, pretty alarming.",
        "tts_text": "Yeah, where a promising candidate actually increased the risk of some men catching the virus. That's uh, pretty alarming.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The researchers warn of a cautionary tale from efforts to create an HIV vaccine over a decade ago, where a promising vaccine candidate actually increased the risk of some men catching the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "It used a modified adenovirus as a vector to deliver HIV genetic material—specifically adenovirus 5, or Ad5.",
        "tts_text": "It used a modified adenovirus as a vector to deliver H I V genetic material-specifically adenovirus five, or Ad5.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The vaccine made use of a modified virus called adenovirus 5 (Ad5) as a vector to transport some of HIVs genetic material into the body.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And they still don't know exactly how it increased transmission risks, but the CDC actually recommended against using Ad5 in future HIV vaccines.",
        "tts_text": "And they still don't know exactly how it increased transmission risks, but the C D C actually recommended against using Ad5 in future H I V vaccines.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Exactly how the vaccine increased the risks of HIV transmission is unknown, but a conference convened by the National Institutes of Health recommended against further use of Ad5 as a vector in HIV vaccines (Dr. Anthony Fauci was lead author of the paper outlining this position.)",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Anthony Fauci was even a co-author on that paper, so it was a serious concern.",
        "tts_text": "Anthony Fauci was even a co-author on that paper, so it was a serious concern.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Exactly how the vaccine increased the risks of HIV transmission is unknown, but a conference convened by the National Institutes of Health recommended against further use of Ad5 as a vector in HIV vaccines (Dr. Anthony Fauci was lead author of the paper outlining this position.)",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "But now, Ad5 is being used in some Covid-19 vaccines, right? Like there are candidates in phase 3 trials in Russia and Pakistan.",
        "tts_text": "But now, Ad5 is being used in some Covidminus nineteen vaccines, right? Like there are candidates in phase three trials in Russia and Pakistan.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Ad5 is used as a vector in some Covid-19 vaccines Science identifies four such candidates that are currently undergoing clinical trials in various countries around the world, including the U.S., with two in large scale phase 3 trials ongoing in Russia and Pakistan.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Exactly. And the authors are stressing that we need to understand Ad5's role in increasing HIV risk before deploying these widely.",
        "tts_text": "Exactly. And the authors are stressing that we need to understand Ad5's role in increasing H I V risk before deploying these widely.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The researchers stressed the need to understand the role Ad5 might play in increasing the risks of HIV in vulnerable populations before developing and deploying vaccines using the vector, adding that informed consent documents should reflect the considerable literature on the risk of HIV acquisition with Ad5 vectors.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Especially in populations with high HIV prevalence, like in sub-Saharan Africa. One of the researchers, Lawrence Corey, said he wouldn't choose an Ad5 vaccine there given other options.",
        "tts_text": "Especially in populations with high H I V prevalence, like in sub-Saharan Africa. One of the researchers, Lawrence Corey, said he wouldn't choose an Ad5 vaccine there given other options.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Lawrence Corey, one of the authors who now co-leads the Covid-19 prevention network in the U.S. that is testing vaccines on behalf of the NIH, told Science that if he were in a sub-Saharan African country, where theres a high prevalence of HIV, I dont see why I would pick an Ad5 vector (vaccine) when there are many other alternative choices.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "It's a tough balance—wanting rapid vaccine deployment but also making sure we don't repeat past mistakes.",
        "tts_text": "It's a tough balance-wanting rapid vaccine deployment but also making sure we don't repeat past mistakes.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": "",
        "confidence": 0.0
      },
      {
        "speaker": "HostB",
        "text": "And they're calling for informed consent documents to clearly reflect this known risk from the literature.",
        "tts_text": "And they're calling for informed consent documents to clearly reflect this known risk from the literature.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "The researchers stressed the need to understand the role Ad5 might play in increasing the risks of HIV in vulnerable populations before developing and deploying vaccines using the vector, adding that informed consent documents should reflect the considerable literature on the risk of HIV acquisition with Ad5 vectors.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Though it's important to note—there's no evidence that current Covid adenovirus vectors, like Johnson & Johnson's, increase HIV risk.",
        "tts_text": "Though it's important to note-there's no evidence that current Covid adenovirus vectors, like Johnson and Johnson's, increase H I V risk.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Some of the leading candidates for a Covid-19 vaccine, including those from Johnson & Johnson and AstraZeneca, use adenoviruses as vectors. There is no evidence that those vectors increase the risk of HIV infection.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Still, it's a conversation that needs to happen now, not after the fact.",
        "tts_text": "Still, it's a conversation that needs to happen now, not after the fact.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": "",
        "confidence": 0.0
      }
    ]
  },
  "generator_model": "DeepSeek-V3.1",
  "batch_index": 2,
  "artist_script": "From the archives of vaccine development, a cautionary tale emerges.\nHostA: So this is a real cautionary tale from the HIV vaccine effort over a decade ago.\nHostB: Yeah, where a promising candidate actually increased the risk of some men catching the virus. That’s uh, pretty alarming.\nHostA: It used a modified adenovirus as a vector to deliver HIV genetic material—specifically adenovirus 5, or Ad5.\nHostB: And they still don’t know exactly how it increased transmission risks, but the CDC actually recommended against using Ad5 in future HIV vaccines.\nHostA: Anthony Fauci was even a co-author on that paper, so it was a serious concern.\nHostB: But now, Ad5 is being used in some Covid-19 vaccines, right? Like there are candidates in phase 3 trials in Russia and Pakistan.\nHostA: Exactly. And the authors are stressing that we need to understand Ad5’s role in increasing HIV risk before deploying these widely.\nHostB: Especially in populations with high HIV prevalence, like in sub-Saharan Africa. One of the researchers, Lawrence Corey, said he wouldn’t choose an Ad5 vaccine there given other options.\nHostA: It’s a tough balance—wanting rapid vaccine deployment but also making sure we don’t repeat past mistakes.\nHostB: And they’re calling for informed consent documents to clearly reflect this known risk from the literature.\nHostA: Though it’s important to note—there’s no evidence that current Covid adenovirus vectors, like Johnson & Johnson’s, increase HIV risk.\nHostB: Still, it’s a conversation that needs to happen now, not after the fact."
}